This is a Validated Antibody Database (VAD) review about mouse Tymp, based on 7 published articles (read how Labome selects the articles), using Tymp antibody in all methods. It is aimed to help Labome visitors find the most suited Tymp antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Tymp synonym: 2900072D10Rik; Ecgf1; PD-ECGF; PDECGF; Pdgfec; thymidine phosphorylase; endothelial cell growth factor 1 (platelet-derived); gliostatin; platelet derived growth factor, endothelial cell; tdRPase
Invitrogen
mouse monoclonal (P-GF.44C) |
| In order to identify biomarkers relevant to treatment outcomes in gastric cancer patients receiving adjuvant S-1 chemotherapy, Invitrogen Tymp antibody (Thermo, P-GF. 44C) was used in immunohistochemistry - paraffin section on human samples at 1:500. PLoS ONE (2015) ncbi |
mouse monoclonal (P-GF.44C) |
| Invitrogen Tymp antibody (Invitrogen, PGF-44C) was used in immunohistochemistry - paraffin section on human samples at 1:100. Anticancer Res (2014) ncbi |
mouse monoclonal (P-GF.44C) |
| Invitrogen Tymp antibody (Thermo Fisher, PGF.44C) was used in immunohistochemistry on human samples at 1:60. Anticancer Res (2014) ncbi |
mouse monoclonal (P-GF.44C) |
| In order to discuss technical factors that influence the analysis of angiogenesis factors in the blood of tumor patients, Invitrogen Tymp antibody (Lab Vision, PGF.44C) was used in ELISA on human samples at 500 ng/ml (fig 1d). Dis Markers (2011) ncbi |
mouse monoclonal (P-GF.44C) |
| In order to assess the use of thymidylate synthase and thymidine phosphorylase as biomarkers to predict clinical outcomes of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer, Invitrogen Tymp antibody (NeoMarkers, PGF.44C) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2d). Cancer Chemother Pharmacol (2011) ncbi |
mouse monoclonal (P-GF.44C) |
| In order to evaluate the anti-tumor effect and mechanisms of cimetidine using a N-butyl-N-(4-hydroxybutyl) nitrosamine-induced model of bladder cancer, Invitrogen Tymp antibody (Lab Vision Corp, PGF.44C) was used in immunohistochemistry - paraffin section on rat samples (fig 2B (c)) and in immunohistochemistry - paraffin section on mouse samples (fig 2A (c)). Oncol Rep (2009) ncbi |
Proteintech Group
rabbit polyclonal |
| Proteintech Group Tymp antibody (Proteintech, 12383-1-AP) was used in western blot on rat samples at 1:1000. J Ovarian Res (2014) ncbi |
Articles Reviewed
- Koumarianou A, Tzeveleki I, Mekras D, Eleftheraki A, Bobos M, Wirtz R, et al. Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression. Anticancer Res. 2014;34:4949-62 pubmed
- Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed
- Chihara Y, Fujimoto K, Miyake M, Hiasa Y, Hirao Y. Anti-tumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamine-induced mouse and rat bladder carcinogenesis. Oncol Rep. 2009;22:23-8 pubmed
contribute
- If you are aware of any publication with knockout studies validating a monoclonal or recombinant antibody, either purchased from a supplier or developed by the author(s), please notify us through feedback.
questions and comments